Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023

Recommend to a Colleague print

 

Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.

11 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• CLINICAL CASES IN MS: A PATIENT WITH MRI LESIONS CONSISTENT WITH MS
  June 27, 2025
• CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF
  June 26, 2025
• EAN HIGHLIGHTS – TUESDAY, JUNE 24, 2025
  June 24, 2025
• EAN HIGHLIGHTS – MONDAY, JUNE 23, 2025
  June 23, 2025
• DMT prescribing in Canada – Part 2
  June 12, 2025

Go back to home page